FDA hopes to accelerate pharmaceutical development and cut drug prices by advancing artificial intelligence and other alternatives to animal testing in drug development, beginning with a pilot program for monoclonal antibodies, the agency said Thursday (April 10). While the initial step is relatively modest, the commitment marks a major policy departure for FDA, where officials had previously said alternatives to animal testing weren’t advanced enough for a full transition. FDA Commissioner Marty Makary said in the statement, “This initiative marks...
